Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase 1/11 results of the EORTC/GIMEMA AML-14A trial

被引：5
|
作者：
Selleslag, Dominik [1 ]
Suciu, Stefan [2 ]
Meloni, Giovanna [3 ]
Muus, Petra [4 ]
Halkes, Constantijn J. M. [5 ]
Venditti, Adriano [6 ]
Ramadan, Safaa M. [2 ,7 ]
Pruijt, Hans [8 ]
Meert, Liv [2 ]
Vignetti, Marco [9 ]
Marie, Jean-Pierre [10 ]
Wittnebel, Sibastian [11 ]
de Witte, Theo
Amadori, Sergio [6 ]
Willemze, Roelof [5 ]
Baron, Fridiric [12 ,13 ]
机构：
[1] AZ St Jan Brugge Oostende, Dept Hematol, Brussels, Belgium
[2] EORTC Headquarters, Brussels, Belgium
[3] Sapienza Univ, Hematol, Rome, Italy
[4] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, Nijmegen, Netherlands
[5] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands
[6] Univ Roma Tor Vergata, Dept Hematol & Biomed & Prevent, Rome, Italy
[7] Ist Europea Oncol, Dept Hematol, Milan, Italy
[8] Jeroen Bosch Med Ctr, Den Bosch, Netherlands
[9] Grp Italiano Malattie Ematol Adulto GIMEMA, Rome, Italy
[10] Hop St Antoine, AP HP, Dept Hematol, Paris, France
[11] ULB, Inst Jules Border, Dept Hematol, Brussels, Belgium
[12] Radboud Univ Nijmegen, Med Ctr, Dept Tumorimmunol, Nijmegen, Netherlands
[13] Univ Liege, GIGA Hematol I3, Liege, Belgium
来源：
HAEMATOLOGICA | 2017年 / 102卷 / 02期
关键词：
CYTARABINE; IDARUBICIN; EORTC;
D O I：
10.3324/haematol.2016.153130
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E47 / E51
页数：5
相关论文
共 20 条
  • [1] Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial
    Selleslag, Dominik L. D.
    Suciu, Stefan
    Meloni, Giovanna
    Muus, Petra
    Halkes, Constantijn J. M.
    Venditti, Adriano
    Ramadan, Safaa M.
    Pruijt, Hans
    Meert, Liv
    Vignetti, Marco
    Marie, Jean-Pierre
    Bron, Dominique
    de Witte, Theo
    Amadori, Sergio
    Willemze, Roelof
    Baron, Frederic
    BLOOD, 2014, 124 (21)
  • [2] Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
    Willemze, R.
    Suciu, S.
    Muus, P.
    Halkes, C. J. M.
    Meloni, G.
    Meert, L.
    Karrasch, M.
    Rapion, J.
    Vignetti, M.
    Amadori, S.
    de Witte, T.
    Marie, J. P.
    ANNALS OF HEMATOLOGY, 2014, 93 (06) : 965 - 975
  • [3] Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
    R. Willemze
    S. Suciu
    P. Muus
    C. J. M. Halkes
    G. Meloni
    L. Meert
    M. Karrasch
    J. Rapion
    M. Vignetti
    S. Amadori
    T. de Witte
    J. P. Marie
    Annals of Hematology, 2014, 93 : 965 - 975
  • [4] Clofarabine in Combination with a Standard Remission Induction Regimen (AraC and idarubicin) in Patients with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Phase I Results of An Ongoing Phase I/II Study of the EORTC-LG and GIMEMA(EORTC GIMEMA 06061/AML-14A trial)
    Willemze, Roelof
    Muus, Petra
    Halkes, Stijn J. M.
    Meloni, Giovanna
    Suciu, Stefan
    Meert, Liv
    Flament, Jocelyne
    Karrasch, Matthias
    Vignetti, Marco
    Amadori, Sergio
    de Witte, Theo M.
    Marie, Jean-Pierre
    BLOOD, 2011, 118 (21) : 1120 - 1121
  • [5] A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-tine therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    Faderl, Stefan
    Ravandi, Farhad
    Huang, Xuelin
    Garcia-Manero, Guillermo
    Ferrajoli, Alessandra
    Estrov, Zeev
    Borthakur, Gautarn
    Verstovsek, Srdan
    Thomas, Deborah A.
    Kwari, Monica
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (05) : 1638 - 1645
  • [6] Low-dose Cytarabine plus Aclarubicin for Patients with Previously Untreated Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Ineligible for Standard-dose Cytarabine plus Anthracycline
    Fukushima, Toshihiro
    Kawabata, Hiroshi
    Sawaki, Toshioki
    Satoh, Tomomi
    Nakamura, Takuji
    Iwao, Haruka
    Nakajima, Akio
    Sakai, Tomoyuki
    Miki, Miyuki
    Fujita, Yoshimasa
    Tanaka, Masao
    Kawanami, Takafumi
    Masaki, Yasufumi
    Okazaki, Toshiro
    Umehara, Hisanori
    ANTICANCER RESEARCH, 2012, 32 (04) : 1347 - 1353
  • [7] A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60years of age
    Buckley, Sarah A.
    Mawad, Raya
    Gooley, Ted A.
    Becker, Pamela S.
    Sandhu, Vicky
    Hendrie, Paul
    Scott, Bart L.
    Wood, Brent L.
    Walter, Roland B.
    Smith, Kelly
    Dean, Carol
    Estey, Elihu H.
    Pagel, John M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (03) : 349 - 355
  • [8] Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
    Cortes, J. E.
    Feldman, E. J.
    Douer, D.
    Raza, A.
    Fruchtman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy
    DeAngelo, Daniel J.
    Sekeres, Mikkael A.
    Ottmann, Oliver G.
    Sanz, Miguel A.
    Naoe, Tomoki
    Taube, Tillmann
    Belsack, Valerie
    Ge, Miaomiao
    Doehner, Hartmut
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S194 - S194
  • [10] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
12